Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International Cohort

Nearly one-quarter of real-world patients with AD would not have met eligibility criteria for pivotal RCTs, yet both biologics and JAK inhibitors demonstrated acceptable safety profiles in these populations. While adverse events were more frequent among ineligible patients receiving JAKis, findings require further investigation to determine their clinical relevance, particularly regarding long-term cardiovascular outcomes.

Authors

Institutions

Publication Details

Journal
Dermatology and Therapy
Published
2026-01-05
DOI
https://doi.org/10.1007/s13555-025-01633-6
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International Cohort

Simone Ribero, Andrea Chiricozzi, Stamatios Gregoriou, Stefano Caccavale et al.
Dermatology and Therapy
Dermatology and Skin Diseases
article

Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International Cohort

Simone Ribero, Andrea Chiricozzi, Stamatios Gregoriou, Stefano Caccavale, Siddhartha Sood, Bruno Kosa Lino Duarte, Silvia Mariel Ferrucci, Spyridon Gkalpakiotis, M. Ortoncelli, Maria João Lopes, Maria João Cruz, Brian Rankin, Francesca Prignano, Antonio Kolios, Ketty Peris, Jensen Yeung, Pedro Farinha, José Oscar Alvarenga, Gilberto Pires Rosa, Gianmarco Silvi, Natalia Rompoti, Elizabeth Lazaridou, Angelo Valerio Marzano, Anna Balato, Jose-Manuel Carrascosa, Vimal Prajapati, Niccolò Gori, Pedro Herranz, Athina Ioanna Daponte, Tiago Torres
article en

Abstract

Nearly one-quarter of real-world patients with AD would not have met eligibility criteria for pivotal RCTs, yet both biologics and JAK inhibitors demonstrated acceptable safety profiles in these populations. While adverse events were more frequent among ineligible patients receiving JAKis, findings require further investigation to determine their clinical relevance, particularly regarding long-term cardiovascular outcomes.

Dermatology and TherapyVol. 16(2)
Università Cattolica del Sacro Cuore (IT), Sunnybrook Health Science Centre (CA), University of Calgary (CA), Universidade do Porto (PT), University of Toronto (CA), University of Milan (IT), University of Campania "Luigi Vanvitelli" (IT), Charles University (CZ), Aristotle University of Thessaloniki (GR), Hospital Universitario La Paz (ES), Women's College Hospital (CA), Health Sciences Centre (CA), Agostino Gemelli University Polyclinic (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Hospital de São João (PT), SKiN Health (CA), University Hospital of Zurich (CH), Administração Regional de Saúde de Lisboa e Vale do Tejo (PT), Probity Medical Research (CA), Andreas Sygros Hospital (GR), Hospital de Santo António (PT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Hospital Universitari Germans Trias i Pujol (ES), University Hospital Kralovske Vinohrady (CZ), University of Florence (IT), University of Turin (IT)
Good health and well-being
Openalex Percentile: Top 98%
Dermatology and Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.